Non-functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Treated With Somatostatin Analogs (SA) Versus NO Treatment - a Prospective, Randomized, Controlled Multicenter Study

Trial Profile

Non-functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Treated With Somatostatin Analogs (SA) Versus NO Treatment - a Prospective, Randomized, Controlled Multicenter Study

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms SANO
  • Most Recent Events

    • 29 Aug 2017 Planned End Date changed from 1 Jun 2023 to 1 Jan 2024.
    • 29 Aug 2017 Planned primary completion date changed from 1 Jun 2022 to 1 Jan 2023.
    • 29 Aug 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top